Please login to the form below
Ocrevus
This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.
Biogen reveals new data for MS therapies Tysabri and Vumerity
treatment. They found that in people receiving Tysabri treatment or Roche’s Ocrevus (ocrelizumab) with baseline impairment, statistically significant improvements were observed in ten of 12 and eight of 12 ... The adjusted annualised rate of
Latest news
-
Roche’s Ocrevus shows significant benefit in early-stage MS patients
The early-stage data bolsters Ocrevus’ claim in the crowded MS market, particularly against Novartis’ Kesimpta (ofatumumab). ... Both Kesimpta and Ocrevus selectively target the immune system’s CD20-positive B cells that damage nerve tissue and
-
Novartis gains EU approval for relapsing MS drug Kesimpta
In particular, both Kesimpta and Ocrevus selectively target the immune system’s CD20-positive B cells that damage nerve tissue and cause disease progression. ... Unlike Kesimpta and Ocrevus, which target CD20-positive B cells, Ponvory inhibits S1P1
-
J&J’s MS drug ponesimod receives approval in the US
As well as the newer therapies, a range of blockbuster drugs are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab).
-
Roche’s Ocrevus boasts positive long-term data in MS
Following two years of using Ocrevus twice-yearly, 75% of relapsing-remitting multiple sclerosis (RRMS) patients had no evidence of disease activity. ... Ocrevus. Patients treated with Ocrevus also experienced an improvement in the majority of their
-
Novartis wins FDA approval for relapsing MS drug Kesimpta
However, the drug will have fierce competition in the market, from rivals such as Roche’s Ocrevus (ocrelizumab) and Sanofi’s Aubagio, despite touting superior efficacy data over the latter. ... Both Kesimpta and Ocrevus selectively target the immune
Roche’s Ocrevus shows significant benefit in early-stage MS patients
Novartis gains EU approval for relapsing MS drug Kesimpta
J&J’s MS drug ponesimod receives approval in the US
Roche’s Ocrevus boasts positive long-term data in MS
More from news
Approximately 21 fully matching, plus 38 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
To succeed, it will have to differentiate from its main direct competitor, the anti-CD20 monoclonal antibody Ocrevus, which has the first-to-market advantage, has labelled indications covering 95% of ... Even if bettering Ocrevus appears unlikely, the
Cortellis Drugs to Watch in 2020 report
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- WHO to test three more potential COVID-19 treatments
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA green lights study of phage-based drug for resistant infections
- First oral antiviral drug for COVID-19 reviewed by Health Canada
PMHub
11 London
The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
